The changes would limit how insurers add patient diagnoses that trigger lucrative extra payments.

Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

The nation’s two largest Medicare Advantage (MA) insurers say they support reforming the federal program to rein in certain ...

This was the stock's second consecutive day of losses.

Humana has endorsed similar policies as Congress seeks spending reductions to offset the cost of President Donald Trump's tax cuts.

Humana has proposed limiting how Medicare Advantage insurance companies can bill the federal government for some diagnoses.

Bernstein SocGen Group analysts reiterated an ‘Outperform’ rating on Humana Inc. (NYSE:HUM) and a $313 price target. The ...

Humana (HUM) backs reforms on extra Medicare Advantage payments from home visits and chart review. Read more here.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

DURHAM, N.C. (WTVD) -- The Anaplastology Clinic in Durham doesn't offer typical medical services. Instead, it helps patients ...

Humana has told congressional staffers that it will support moves that would curtail billing practices worth billions in ...

Humana Inc. closed 43.21% below its 52-week high of $406.46, which the company reached on July 18th.